Some very exciting news for those of us who have been following obicetrapib, the new oral CETP inhibitor developed by NewAmsterdam Pharma.
Today, September 21, 2026, the European Commission granted marketing authorization for obicetrapib, marking its first regulatory approval anywhere in the world.
Two versions have been approved:
Ubeslo® — obicetrapib 10 mg as a once-daily tablet.
Evlarco® — a single tablet combining obicetrapib 10 mg with ezetimibe 10 mg.
This is particularly interesting because obicetrapib has produced substantial LDL-C reductions in Phase 3 trials. NewAmsterdam reports reductions of up to approximately 40% with obicetrapib alone and approximately 50% when combined with ezetimibe, compared with placebo. Tolerability in these trials was reported as comparable to placebo.
Obicetrapib is a CETP inhibitor, but unlike earlier drugs in this class, it is a low-dose oral therapy being developed primarily for its ability to substantially lower LDL-C and other atherogenic lipoproteins.
For those of us interested in APOE4 and cardiovascular risk reduction, this is a development worth watching closely. Cardiovascular health and brain health are intimately connected, although it is important to emphasize that obicetrapib is not approved as an Alzheimer’s treatment or prevention therapy.
What happens next?
European approval does not necessarily mean you can walk into a pharmacy tomorrow and get it. Menarini holds the European commercialization rights, and we are now waiting for details regarding country-by-country launch dates, pricing and actual pharmacy availability.
But the big regulatory hurdle has now been crossed.
Obicetrapib is officially an approved drug.
Exciting! I sure hope it works out.